Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib in advanced or metastatic GEP-NET
NCT01994213Phase 2Terminated
- Sponsor
- Hengrui
- Start
- Oct 2011
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of famitinib in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Hengrui. Started Oct 2011; status: terminated.
02
Drugs
famitinib
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT01994213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994213.